Ken Griffin Xenon Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 120,045 shares of XENE stock, worth $4.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,045

Previous 7,700 1459.03%

Holding current value

$4.32 Million

Previous $258,000 1356.2%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$28.23 - $38.37 $16 Million - $21.8 Million	-567,043 Reduced 82.53%	120,045 $3.76 Million
Q1 2025 May 15, 2025	BUY	$33.55 - $40.74 $12.1 Million - $14.7 Million	359,785 Added 109.92%	687,088 $23.1 Million
Q4 2024 Feb 14, 2025	SELL	$38.14 - $45.74 $15.1 Million - $18.1 Million	-395,201 Reduced 54.7%	327,303 $12.8 Million
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $1.67 Million - $2.03 Million	-46,222 Reduced 6.01%	722,504 $28.4 Million
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $18.8 Million - $22.7 Million	-518,349 Reduced 40.27%	768,726 $30 Million
Q1 2024 May 15, 2024	BUY	$42.66 - $50.04 $863,054 - $1.01 Million	20,231 Added 1.6%	1,287,075 $55.4 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $15.6 Million - $25.2 Million	543,320 Added 75.09%	1,266,844 $58.4 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $7.6 Million - $8.84 Million	222,512 Added 44.41%	723,524 $24.7 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $12.9 Million - $16.1 Million	-370,222 Reduced 42.49%	501,012 $19.3 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $9.81 Million - $11.8 Million	-293,173 Reduced 25.18%	871,234 $31.2 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $740,709 - $883,429	22,405 Added 1.96%	1,164,407 $45.9 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $15.6 Million - $20.2 Million	-506,037 Reduced 30.71%	1,142,002 $41.2 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $5.27 Million - $7.28 Million	206,959 Added 14.36%	1,648,039 $50.1 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $3.85 Million - $5.08 Million	153,277 Added 11.9%	1,441,080 $44.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $6.97 Million - $15.8 Million	446,587 Added 53.09%	1,287,803 $40.2 Million
Q3 2021 Nov 15, 2021	SELL	$14.86 - $19.45 $3.01 Million - $3.94 Million	-202,327 Reduced 19.39%	841,216 $12.9 Million
Q2 2021 Aug 16, 2021	BUY	$16.81 - $20.0 $13.8 Million - $16.4 Million	820,991 Added 368.9%	1,043,543 $19.4 Million
Q1 2021 May 17, 2021	BUY	$13.65 - $21.31 $2.06 Million - $3.22 Million	151,002 Added 211.04%	222,552 $3.98 Million
Q4 2020 Feb 16, 2021	SELL	$9.49 - $16.04 $2.28 Million - $3.85 Million	-240,132 Reduced 77.04%	71,550 $1.1 Million
Q3 2020 Nov 16, 2020	SELL	$10.82 - $13.35 $850,213 - $1.05 Million	-78,578 Reduced 20.13%	311,682 $3.45 Million
Q2 2020 Aug 14, 2020	SELL	$10.21 - $14.9 $1.18 Million - $1.72 Million	-115,769 Reduced 22.88%	390,260 $4.89 Million
Q1 2020 May 15, 2020	BUY	$8.08 - $17.57 $2.21 Million - $4.81 Million	273,764 Added 117.87%	506,029 $5.74 Million
Q4 2019 Feb 14, 2020	SELL	$8.11 - $14.65 $322,940 - $583,363	-39,820 Reduced 14.64%	232,265 $3.05 Million
Q3 2019 Nov 14, 2019	SELL	$8.74 - $10.51 $1.45 Million - $1.74 Million	-165,495 Reduced 37.82%	272,085 $2.45 Million
Q2 2019 Aug 14, 2019	SELL	$8.51 - $10.75 $1.82 Million - $2.31 Million	-214,443 Reduced 32.89%	437,580 $4.32 Million
Q1 2019 May 15, 2019	SELL	$6.39 - $10.42 $1.19 Million - $1.94 Million	-186,279 Reduced 22.22%	652,023 $0
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $473,298 - $1.06 Million	84,367 Added 11.19%	838,302 $5.29 Million
Q3 2018 Nov 13, 2018	BUY	$9.0 - $14.9 $6.79 Million - $11.2 Million	753,935 New	753,935 $0

Others Institutions Holding XENE

# of Institutions

220

Shares Held

73.2M

Call Options Held

336K

Put Options Held

309K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.24B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account